The stock of Guardant Health Inc (NASDAQ: GH) has decreased by -2.12 when compared to last closing price of 50.09.Despite this, the company has seen a gain of 2.66% in its stock price over the last five trading days. businesswire.com reported 2025-06-10 that PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world’s most urgent challenges. Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC.
Is It Worth Investing in Guardant Health Inc (NASDAQ: GH) Right Now?
GH has 36-month beta value of 1.40. Analysts have mixed views on the stock, with 15 analysts rating it as a “buy,” 7 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for GH is 117.62M, and currently, short sellers hold a 7.54% ratio of that float. The average trading volume of GH on June 12, 2025 was 2.25M shares.
GH’s Market Performance
GH stock saw an increase of 2.66% in the past week, with a monthly gain of 17.69% and a quarterly increase of 13.76%. The volatility ratio for the week is 2.24%, and the volatility levels for the last 30 days are 3.36% for Guardant Health Inc (GH). The simple moving average for the last 20 days is 15.16% for GH’s stock, with a simple moving average of 36.08% for the last 200 days.
Analysts’ Opinion of GH
Many brokerage firms have already submitted their reports for GH stocks, with Mizuho repeating the rating for GH by listing it as a “Outperform.” The predicted price for GH in the upcoming period, according to Mizuho is $55 based on the research report published on April 10, 2025 of the current year 2025.
Barclays, on the other hand, stated in their research note that they expect to see GH reach a price target of $60. The rating they have provided for GH stocks is “Overweight” according to the report published on January 23rd, 2025.
Guggenheim gave a rating of “Buy” to GH, setting the target price at $36 in the report published on June 28th of the previous year.
GH Trading at 12.93% from the 50-Day Moving Average
After a stumble in the market that brought GH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.35% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at GH starting from Talasaz AmirAli, who sale 77,853 shares at the price of $50.09 back on Jun 09 ’25. After this action, Talasaz AmirAli now owns 2,069,456 shares of Guardant Health Inc, valued at $3,899,937 using the latest closing price.
Talasaz AmirAli, the Co-Chief Executive Officer of Guardant Health Inc, sale 39,751 shares at $50.07 during a trade that took place back on Jun 06 ’25, which means that Talasaz AmirAli is holding 2,147,309 shares at $1,990,420 based on the most recent closing price.
Stock Fundamentals for GH
Current profitability levels for the company are sitting at:
- -0.59 for the present operating margin
- 0.61 for the gross margin
The net margin for Guardant Health Inc stands at -0.54. The total capital return value is set at -0.41. Equity return is now at value -4584.47, with -27.33 for asset returns.
Based on Guardant Health Inc (GH), the company’s capital structure generated 1.24 points at debt to capital in total, while cash flow to debt ratio is standing at -0.21. The debt to equity ratio resting at -5.21. The interest coverage ratio of the stock is -166.83.
Currently, EBITDA for the company is -390.12 million with net debt to EBITDA at -1.53. When we switch over and look at the enterprise to sales, we see a ratio of 8.63. The receivables turnover for the company is 6.71for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.11.
Conclusion
To put it simply, Guardant Health Inc (GH) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
